Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Inclusion Criteria: 1. Diagnosed with AML (the diagnostic criteria refer to WHO2022 standard, non-APL), and have not received systemic anti-leukemia therapy (except hydroxyurea, low-dose cytarabine and other tumor reduction pretreatments); 2. Age ≥18 years old; 3. ECOG≤4; 4. The fertile woman agrees to use effective contraception during the treatment period and up to 3 months after the end of the treatment; Sign the informed consent form. Exclusion Criteria: 1. Known history of allergy to the investigational drug; 2. Resistance to azacytidine, azacitidine, Venetoclax; 3. Inability to take oral medication; 4. Combined with uncontrolled active infections (including bacterial, fungal or viral infections); 5. Combined with uncontrolled major organ dysfunction: cardiac insufficiency, decompensated liver insufficiency, moderate/severe renal insufficiency, etc.; 6. Participating in other clinical studies that affect the main purpose of this study; Patients deemed unsuitable for participation in this study.